The stock of Kura Oncology Inc (KURA) has seen a -3.83% decrease in the past week, with a -3.23% drop in the past month, and a 35.19% flourish in the past quarter. The volatility ratio for the week is 4.37%, and the volatility levels for the past 30 days are at 5.39% for KURA. The simple moving average for the past 20 days is -6.34% for KURA’s stock, with a 55.79% simple moving average for the past 200 days.
Is It Worth Investing in Kura Oncology Inc (NASDAQ: KURA) Right Now?
The stock has a 36-month beta value of 0.88. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KURA is 63.54M, and at present, short sellers hold a 16.22% of that float. On April 05, 2024, the average trading volume of KURA was 1.46M shares.
KURA) stock’s latest price update
The stock of Kura Oncology Inc (NASDAQ: KURA) has increased by 0.10 when compared to last closing price of 20.34.Despite this, the company has seen a loss of -3.83% in its stock price over the last five trading days. GlobeNewsWire reported 2024-02-22 that SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
Analysts’ Opinion of KURA
Many brokerage firms have already submitted their reports for KURA stocks, with Mizuho repeating the rating for KURA by listing it as a “Buy.” The predicted price for KURA in the upcoming period, according to Mizuho is $26 based on the research report published on December 22, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see KURA reach a price target of $31. The rating they have provided for KURA stocks is “Buy” according to the report published on August 11th, 2023.
Scotiabank gave a rating of “Sector Perform” to KURA, setting the target price at $10.50 in the report published on July 27th of the previous year.
KURA Trading at -1.95% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.76% of loss for the given period.
Volatility was left at 5.39%, however, over the last 30 days, the volatility rate increased by 4.37%, as shares sank -10.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +51.71% upper at present.
During the last 5 trading sessions, KURA fell by -3.83%, which changed the moving average for the period of 200-days by +89.22% in comparison to the 20-day moving average, which settled at $21.62. In addition, Kura Oncology Inc saw 41.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from DALE STEPHEN, who sale 4,825 shares at the price of $21.55 back on Jan 30 ’24. After this action, DALE STEPHEN now owns 38,817 shares of Kura Oncology Inc, valued at $103,980 using the latest closing price.
DALE STEPHEN, the Chief Medical Officer of Kura Oncology Inc, sale 7,158 shares at $17.80 during a trade that took place back on Jan 29 ’24, which means that DALE STEPHEN is holding 43,642 shares at $127,416 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -127.67 for the present operating margin
- 0.33 for the gross margin
The net margin for Kura Oncology Inc stands at -117.77. The total capital return value is set at -0.39. Equity return is now at value -37.34, with -33.72 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -11.52. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -209.21.
Currently, EBITDA for the company is -164.96 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 1204.75. The receivables turnover for the company is 0.45for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.26.
Conclusion
To sum up, Kura Oncology Inc (KURA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
